ACT Proposes Roughly NZ$2 Billion National Cancer Centre Using Public and Private Capital

ACT New Zealand has proposed a purpose-built National Cancer Centre with campuses in Auckland and Christchurch, putting an indicative capital requirement of about NZ$2 billion behind a plan to concentrate advanced cancer treatment, research and clinical trials in two large hubs. The party says the figure is an early estimate rather than an approved budget, with the final cost to depend on the scope, design, financing structure and facilities chosen through detailed business cases.

The funding model is as important to ACT’s proposal as the buildings themselves. The Crown would not necessarily own or finance every component. ACT wants to combine public-private partnership financing, charitable donations, existing Crown health investment and other private capital, while Health New Zealand would become a major customer by locating relevant Auckland and Christchurch cancer services at the new campuses and purchasing care for publicly funded patients.

ACT’s Beyond Tomorrow policy, released on August 21, says the next step would be detailed business cases developed with the University of Auckland’s Department of Cancer Sciences and the Christchurch Cancer Foundation. The document does not yet set a construction timetable, specify how much of the estimated NZ$2 billion would come from taxpayers, philanthropy or private investors, or set out the long-term service-payment arrangements that would underpin privately financed facilities.

Two campuses would combine treatment, research and clinical trials

The proposed centre would bring together complex surgery, radiation oncology, molecular diagnostics and genomics, advanced imaging, systemic therapies, intensive care and clinical trials ranging from early-phase studies through Phase III. ACT also wants the institution to work with universities, research institutes, private providers, industry partners and patient organisations, with the stated aim of creating enough scale to recruit specialists and translate research into treatment more quickly.

Under the geographic model in the policy, Christchurch would serve the South Island and lower North Island, which ACT estimates at about 40% of the country’s population, while the Auckland campus would serve the remaining 60%. The plan is not to move all cancer care in New Zealand into two hospitals. Rather, the campuses are framed as national centres for complex treatment, research and specialised services within a broader health system that would continue to provide cancer care around the country.

An independent, not-for-profit National Cancer Centre Foundation would sit at the centre of the model. The foundation would be established early so it could raise philanthropic money while the campuses were being scoped and designed. Major donors could receive naming rights for appropriate parts of the centre, and ACT says an exceptionally large contribution could potentially carry naming rights for a hospital.

For publicly funded care, the policy envisages Health New Zealand contracting with the centre for the facilities and clinical services it needs. That makes the proposal different from a simple Crown-funded hospital construction programme. Public money would still pay for treatment, but some of the infrastructure could be financed or owned by private parties, depending on the final arrangements. ACT also raises private care and, in the longer term, medical tourism as possible additional sources of activity, although it provides no revenue forecasts for either.

Financing plan leans on public-private partnerships and philanthropy

The approximately NZ$2 billion capital estimate is based, according to ACT, on comparable international cancer centres and major New Zealand hospital projects. It argues that part of the spending should be viewed against health infrastructure investment that would be required anyway as existing facilities age and demand grows. Health New Zealand’s 2024/25 annual report separately said its 10-year infrastructure investment plan identified more than NZ$20 billion of investment required to meet future health needs.

Part of the plan is to examine whether capital already earmarked for replacing or expanding cancer infrastructure could be redirected into the National Cancer Centre instead of funding separate projects. Private capital could finance facilities considered suitable for a public-private partnership, while philanthropy could add equipment, research capability or capacity beyond what the Crown would otherwise fund. ACT says the Crown’s continuing financial exposure would arise mainly through Health New Zealand buying cancer care and using the centre’s facilities, but the policy does not specify the proposed debt-equity mix, private-investor return requirements or annual service charges.

A separate tax change is intended to strengthen the philanthropic side of the funding model. The Taxation (Budget Measures) Act 2026 introduced a ceiling under which donations eligible for the individual donation tax credit will be limited to the lower of NZ$100,000 or the donor’s taxable income from April 1, 2027. The credit rate remains one-third, producing a maximum annual credit of NZ$33,333.33 under the new ceiling. ACT proposes removing that cap for charitable giving generally, not just donations connected to the cancer centre.

That tax proposal could matter if the party succeeds in attracting very large gifts, but it does not remove the need for a detailed funding plan. The size of the Crown contribution, how private finance would be repaid, what assets would sit with the foundation and how Health New Zealand contracts would be priced are all unresolved. Those details would determine how financing and performance risk is divided between private partners and the Crown, and how public costs are spread over time.

Existing cancer planning gives the concept a head start, not an approval

New Zealand is preparing for a rising cancer burden. Te Aho o Te Kahu, the Cancer Control Agency, said in its 2025 State of Cancer report that more than 30,000 people were expected to be diagnosed in 2025 and that annual diagnoses are projected to exceed 45,000 by 2044. The agency also reported persistent workforce pressure across much of the cancer system, giving the proposal a clear capacity and recruitment context even though the benefits of ACT’s chosen structure would still have to be demonstrated through the business-case process.

Government discussion of a comprehensive-centre model also predates ACT’s new proposal. A proactively released Ministry of Health aide-memoire from May 2025 records that Cancer Control Agency officials had met the Christchurch Cancer Foundation about a proposed comprehensive cancer centre in Christchurch, with an understanding that another centre was envisaged in Auckland. The memo said officials were examining the foundation’s intended funding model and described the concept’s rationale as creating enough critical mass in treatment, training and research to improve care, recruitment and clinical research activity.

None of that earlier government work amounts to approval of ACT’s NZ$2 billion plan. It does show that the core idea of comprehensive centres in Christchurch and Auckland has already been discussed inside the health system. ACT’s version adds a national foundation, an explicit public-private financing strategy, a broad charitable-tax change and a commitment to direct Health New Zealand services into the two campuses.

The next financial test is therefore the business case rather than the headline capital number. ACT would need to define which existing services move, which assets are replaced rather than duplicated, how public access is protected, how private financing is structured and what the ongoing operating commitments would cost. Until those decisions are made, the roughly NZ$2 billion figure remains an indicative capital requirement, not a committed Crown appropriation or a fully financed construction programme.